Adalimumab Biosimilar Market Expand Lucratively & Grow at a CAGR of 23.2% to…
<!-- Name:DistributionId Value:8803426 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
adalimumab
Adalimumab Biosimilar Market is Probable to Influence the Value of USD 3431.48…
<!-- Name:DistributionId Value:8801014 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi…
AVT02 as Simlandi™ is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure Alvotech (NASDAQ: ALVO) and Bioventure, a wholly owned subsidiary of…
Alvotech og Bioventure fá markaðsleyfi fyrir AVT02 (adalimumab) í Sádi-Arabíu
Alvotech (NASDAQ: ALVO) og Bioventure, dótturfyrirtæki GlobalOne Healthcare Holding LLC, heilbrigðissviðs YAS Holding LLC, tilkynntu í dag að lyfja- og matvælaeftirlit Sádi-Arabíu (SFDA)…
Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe
Hukyndra® (adalimumab) launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in…
Upadacitinib Versus Adalimumab in Psoriatic Arthritis
Among patients with psoriatic arthritis (PsA), treatment with upadacitinib (Rinvoq) led to greater…
Junshi Biosciences Announces Approval of Supplemental Application for Additional…
SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical…
CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage…
PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- A correction has been issued for the release disseminated under the same headline on Thursday, November 15th by 180 Life Sciences…
Another Adalimumab Biosimilar Seems Set for Interchangeability
PHILADELPHIA -- Pfizer has made the case for gaining the coveted "interchangeability" status for its adalimumab biosimilar…
Samsung Bioepis Presents Three-year Follow-up Data of Adalimumab Biosimilar SB5 in…
Long term follow-up data from British Association of Dermatologics and Immunomodulators Register (BADBIR) shows safety and effectiveness of SB5 in patients with psoriasis who have started…